Kapadi

Executive Summary

Kapadi is a specialized oncology-focused Contract Research Organization (CRO) that accelerates complex clinical trials for biotech partners. Founded in 2020 and headquartered in San Francisco, Kapadi leverages deep expertise in immuno-oncology and cell & gene therapies, supported by a global network of oncology sites and a strategic partnership with Moffitt Cancer Center. The company provides full-service and functional service provider (FSP) solutions, guiding assets from concept to clinic. By focusing exclusively on oncology, Kapadi differentiates itself from generalist CROs, offering targeted operational efficiencies and scientific insights. Its partnership with Moffitt enhances access to leading researchers and patient populations, potentially shortening trial timelines. Given the growing demand for specialized CRO services in the oncology space, Kapadi is well-positioned to capture market share. Kapadi's future growth depends on expanding its client base and deepening relationships with key sites. The company's focus on cell and gene therapies aligns with a high-growth segment in oncology. However, as a private company with limited public information, its traction is not fully visible. The strategic partnership with Moffitt provides a strong foundation, but competition from larger CROs remains a challenge. Overall, Kapadi represents a promising niche player in the CRO industry.

Upcoming Catalysts (preview)

• TBDExpansion of Moffitt Cancer Center Partnership60% success
• TBDMajor New Client or Contract Win70% success
• TBDMilestone Achievement in Cell/Gene Therapy Trial50% success